» Articles » PMID: 22837985

Adhesion Receptors As Therapeutic Targets for Circulating Tumor Cells

Overview
Journal Front Oncol
Specialty Oncology
Date 2012 Jul 28
PMID 22837985
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis contributes to >90% of cancer-associated mortality. Though primary tumors can be removed by surgical resection or chemo/radiotherapy, metastatic disease is a great challenge to treatment due to its systemic nature. As metastatic "seeds," circulating tumor cells (CTCs) are believed to be responsible for dissemination from a primary tumor to anatomically distant organs. Despite the possibility of physical trapping of CTCs in microvessels, recent advances have provided insights into the involvement of a variety of adhesion molecules on CTCs. Such adhesion molecules facilitate direct interaction with the endothelium in specific tissues or indirectly through leukocytes. Importantly, significant progress has been made in understanding how these receptors confer enhanced invasion and survival advantage during hematogenous circulation of CTCs through recruitment of macrophages, neutrophils, platelets, and other cells. This review highlights the identification of novel adhesion molecules and how blocking their function can compromise successful seeding and colonization of CTCs in new microenvironment. Encouraged by existing diagnostic tools to identify and isolate CTCs, strategic targeting of these adhesion molecules to deliver conventional chemotherapeutics or novel apoptotic signals is discussed for the neutralization of CTCs in the circulation.

Citing Articles

Role of Cell Adhesion in Cancer Metastasis Formation: A Review.

Burcik D, Macko J, Podrojkova N, Demeterova J, Stano M, Orinak A ACS Omega. 2025; 10(6):5193-5213.

PMID: 39989825 PMC: 11840620. DOI: 10.1021/acsomega.4c08140.


Dielectrophoretic capture and electrochemical enzyme-linked immunosorbent assay of single melanoma cells at an array of interlocked spiral bipolar electrodes.

Clark M, Moser H, Anand R ChemElectroChem. 2024; 11(15).

PMID: 39483376 PMC: 11526340. DOI: 10.1002/celc.202400182.


Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?.

Fabisiewicz A, Szostakowska-Rodzos M, Grzybowska E Int J Mol Sci. 2024; 25(19).

PMID: 39408942 PMC: 11476589. DOI: 10.3390/ijms251910612.


CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma.

Stenzel P, Schindeldecker M, Seidmann L, Herpel E, Hohenfellner M, Hatiboglu G Pathobiology. 2023; 91(3):219-229.

PMID: 37963432 PMC: 11151972. DOI: 10.1159/000535201.


Detection of Single Cancer Cell Multidrug Resistance With Single Cell Bioanalyzer.

Cai J, Fan X, Li R, Lin H, Li M, Song Q Technol Cancer Res Treat. 2023; 22:15330338231187239.

PMID: 37424497 PMC: 10336763. DOI: 10.1177/15330338231187239.


References
1.
Matsuura N, Narita T, Hiraiwa N, Hiraiwa M, Murai H, Iwase T . Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer. Int J Oncol. 1998; 12(5):1157-64. DOI: 10.3892/ijo.12.5.1157. View

2.
Rana K, Reinhart-King C, King M . Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin. Mol Pharm. 2012; 9(8):2219-27. PMC: 3412427. DOI: 10.1021/mp300073j. View

3.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

4.
Amirkhosravi A, Meyer T, Chang J, Amaya M, Siddiqui F, Desai H . Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002; 87(6):930-6. View

5.
Iadocicco K, Monteiro L, Chaui-Berlinck J . A theoretical model for estimating the margination constant of leukocytes. BMC Physiol. 2002; 2:3. PMC: 100780. DOI: 10.1186/1472-6793-2-3. View